Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted and appeared in  MedicationType 2 DiabetesIssue 611

FDA Approves Eli Lilly Diabetes Combo Drug Jentadueto

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company announced the FDA approved Jentadueto™ (linagliptin/metformin hydrochloride) tablets....

Advertisement

Drawing from the momentum of Tradjenta™ (linagliptin) tablets -- approved for U.S. marketing in May 2011 – JENTADUETO combines linagliptin and metformin into a new, single-tablet option, taken twice daily and comes in 3 different dosages.

JENTADUETO is a prescription medication used along with diet and exercise to improve glycemic control in adults with type 2 diabetes when treatment with both linagliptin and metformin is appropriate. JENTADUETO is not for the treatment of type 1 diabetes or diabetic ketoacidosis (increased ketones in the blood or urine). It has not been studied in combination with insulin.

At the maximum dose, JENTADUETO demonstrated placebo-corrected reductions in hemoglobin A1Clevels of up to 1.7 percent. It can be used alone or in combination with a sulfonylurea, another commonly prescribed medication for type 2 diabetes.

The JENTADUETO label contains a boxed warning because the addition of metformin which may cause a rare but serious condition called lactic acidosis (a build-up of lactic acid in the blood) that can cause death. It is not for treatment of type 1 diabetes or diabetic ketoacidosis and has not been studied in combination with insulin. The dosage should be individualized based on the patient's current regimen and the maximum recommended dose is 2.5 mg linagliptin/1000 mg metformin twice a day. It should be given twice daily with meals, with gradual dose escalation to reduce the gastrointestinal side effects due to metformin.

It comes in 3 dosage forms, 2.5 mg linagliptin/500 mg metformin hydrochloride, 2.5 mg linagliptin/850 mg metformin hydrochloride and 2.5 mg linagliptin/1000 mg metformin hydrochloride.

Contraindications include: renal impairment, metabolic acidosis and hypersensitivity to linagliptin or metformin.

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company news release

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 01 February, 2012 and appeared in  MedicationType 2 DiabetesIssue 611

Past five issues: SGLT-2 Inhibitors Special Edition May 2015 | Diabetes Clinical Mastery Series Issue 242 | Issue 782 | GLP-1 Special Editions May 2015 | Diabetes Clinical Mastery Series Issue 241 |

2015 Most Popular Articles:

Neuropathy Due to Vitamin B-12 Deficiency, Not Diabetes
Posted April 30, 2015
What Is the Medicare Diabetes Prevention Act?
Posted May 08, 2015
Is Diet or Exercise the Best Way to Reduce Diabetes Risk?
Posted May 15, 2015
Fish Oil May Help with Diabetic Neuropathy
Posted May 15, 2015
GLP-1 Analog May Help with NAFLD and Nonalcoholic Steatohepatitis
Posted May 15, 2015
SGLT-2 Inhibitors: Teach from the Start and Manage Expectations
Posted May 03, 2015
Vitamin D Supplements May Help Patients Lose Weight
Posted May 15, 2015
Treating Sleep Apnea with CPAP Nightly Can Lower Diabetes Risk
Posted May 08, 2015
Summary of Standards of Care for Diabetes for Primary Care
Posted April 30, 2015
Metformin Reported in Use with Only 3.7% of Those with Prediabetes
Posted April 30, 2015


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Richard K. Bernstein, MD | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |

Cast Your Vote
Do you believe that the FDA takes too much time to approve a drug?
CME/CE of the Week
Presented by CardioCareLive
Category: Cardiology



Search Articles On Diabetes In Control